Abstract
Background aims: The impact of chronic lymphatic leukemia (CLL) tumor burden on the autologous immune system has already been demonstrated. This study attempted to elucidate the molecular mechanisms underlying T-cell immunologic deficiencies in CLL. Methods: Freshly isolated CD3+ T cells from patients with a diagnosis of CLL and healthy donors were analyzed by gene expression profiling. Activated T cells from 20 patients with CLL were tested in vitro for cytotoxicity against mutated and unmutated autologous B cells and DAUDI, K562 and P815 cell lines. To investigate T-cell mediated cytotoxicity in vivo, we co-transplanted OKT3-activated T lymphocytes and autologous B-cell CLL (B-CLL) cells into NOD/SCID mice. Results: Gene expression profiles of peripheral blood T cells from B-CLL patients showed 25 down-regulated, and 31 up-regulated, genes that were mainly involved in cell differentiation, proliferation, survival, apoptosis, cytoskeleton formation, vesicle trafficking and T-cell activation. After culture, the T-cell count remained unchanged, CD8 cells expanded more than CD4 and a cytotoxicity index > 30% was present in 5/20 patients. Cytotoxicity against B autologous leukemic cells did not correlate with B-cell mutational status. Only activated T cells exerting cytotoxicity against autologous leukemic B cells prevented CLL in a human-mouse chimera. Conclusions: This study indicates that patients with CLL are affected by a partial immunologic defect that might be somewhat susceptible to repair. This study identifies the molecular pathways underlying T-cell deficiencies in CLL and shows that cytotoxic T-cell functions against autologous B-CLL can be rebuilt at least in part in vitro and in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 86-96 |
| Number of pages | 11 |
| Journal | Cytotherapy |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Autologous anti-tumoral activity
- Chronic lymphatic leukemia
- Gene expression profiling
- NOD/SCID mice
- OKT3 activation
- T lymphocytes
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Molecular Medicine
Cite this
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. / Di Ianni, Mauro; Moretti, Lorenzo; Terenzi, Adelmo; Bazzucchi, Federico; Del Papa, Beatrice; Bazzucchi, Moira; Ciurnelli, Raffaella; Lucchesi, Alessandro; Sportoletti, Paolo; Rosati, Emanuela; Marconi, Pier Francesco; Falzetti, Franca; Tabilio, Antonio.
In: Cytotherapy, Vol. 11, No. 1, 2009, p. 86-96.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo
AU - Di Ianni, Mauro
AU - Moretti, Lorenzo
AU - Terenzi, Adelmo
AU - Bazzucchi, Federico
AU - Del Papa, Beatrice
AU - Bazzucchi, Moira
AU - Ciurnelli, Raffaella
AU - Lucchesi, Alessandro
AU - Sportoletti, Paolo
AU - Rosati, Emanuela
AU - Marconi, Pier Francesco
AU - Falzetti, Franca
AU - Tabilio, Antonio
PY - 2009
Y1 - 2009
N2 - Background aims: The impact of chronic lymphatic leukemia (CLL) tumor burden on the autologous immune system has already been demonstrated. This study attempted to elucidate the molecular mechanisms underlying T-cell immunologic deficiencies in CLL. Methods: Freshly isolated CD3+ T cells from patients with a diagnosis of CLL and healthy donors were analyzed by gene expression profiling. Activated T cells from 20 patients with CLL were tested in vitro for cytotoxicity against mutated and unmutated autologous B cells and DAUDI, K562 and P815 cell lines. To investigate T-cell mediated cytotoxicity in vivo, we co-transplanted OKT3-activated T lymphocytes and autologous B-cell CLL (B-CLL) cells into NOD/SCID mice. Results: Gene expression profiles of peripheral blood T cells from B-CLL patients showed 25 down-regulated, and 31 up-regulated, genes that were mainly involved in cell differentiation, proliferation, survival, apoptosis, cytoskeleton formation, vesicle trafficking and T-cell activation. After culture, the T-cell count remained unchanged, CD8 cells expanded more than CD4 and a cytotoxicity index > 30% was present in 5/20 patients. Cytotoxicity against B autologous leukemic cells did not correlate with B-cell mutational status. Only activated T cells exerting cytotoxicity against autologous leukemic B cells prevented CLL in a human-mouse chimera. Conclusions: This study indicates that patients with CLL are affected by a partial immunologic defect that might be somewhat susceptible to repair. This study identifies the molecular pathways underlying T-cell deficiencies in CLL and shows that cytotoxic T-cell functions against autologous B-CLL can be rebuilt at least in part in vitro and in vivo.
AB - Background aims: The impact of chronic lymphatic leukemia (CLL) tumor burden on the autologous immune system has already been demonstrated. This study attempted to elucidate the molecular mechanisms underlying T-cell immunologic deficiencies in CLL. Methods: Freshly isolated CD3+ T cells from patients with a diagnosis of CLL and healthy donors were analyzed by gene expression profiling. Activated T cells from 20 patients with CLL were tested in vitro for cytotoxicity against mutated and unmutated autologous B cells and DAUDI, K562 and P815 cell lines. To investigate T-cell mediated cytotoxicity in vivo, we co-transplanted OKT3-activated T lymphocytes and autologous B-cell CLL (B-CLL) cells into NOD/SCID mice. Results: Gene expression profiles of peripheral blood T cells from B-CLL patients showed 25 down-regulated, and 31 up-regulated, genes that were mainly involved in cell differentiation, proliferation, survival, apoptosis, cytoskeleton formation, vesicle trafficking and T-cell activation. After culture, the T-cell count remained unchanged, CD8 cells expanded more than CD4 and a cytotoxicity index > 30% was present in 5/20 patients. Cytotoxicity against B autologous leukemic cells did not correlate with B-cell mutational status. Only activated T cells exerting cytotoxicity against autologous leukemic B cells prevented CLL in a human-mouse chimera. Conclusions: This study indicates that patients with CLL are affected by a partial immunologic defect that might be somewhat susceptible to repair. This study identifies the molecular pathways underlying T-cell deficiencies in CLL and shows that cytotoxic T-cell functions against autologous B-CLL can be rebuilt at least in part in vitro and in vivo.
KW - Autologous anti-tumoral activity
KW - Chronic lymphatic leukemia
KW - Gene expression profiling
KW - NOD/SCID mice
KW - OKT3 activation
KW - T lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=62149084085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62149084085&partnerID=8YFLogxK
U2 - 10.1080/14653240802666035
DO - 10.1080/14653240802666035
M3 - Article
C2 - 19153855
AN - SCOPUS:62149084085
VL - 11
SP - 86
EP - 96
JO - Cytotherapy
JF - Cytotherapy
SN - 1465-3249
IS - 1
ER -